Evidence map›Paper›PMID 32125512›Full record

ArticleHistochemistry and cell biology2020

Detection of doxorubicin, cisplatin and therapeutic antibodies in formalin-fixed paraffin-embedded human cancer cells.

Lukas Böckelmann, Christin Starzonek, Ann-Christin Niehoff, Uwe Karst, Jürgen Thomale, Hartmut Schlüter, Carsten Bokemeyer, Achim Aigner, Udo Schumacher

Open access · hybridAbstract read
In one paragraph

Article in Histochemistry and cell biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. In focus in HCB.Histochemistry and cell biology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Lukas BöckelmannInstitute of Anatomy and Experimental Morphology, Center for Experimental Medicine, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. l.boeckelmann@uke.de.ORCID http://orcid.org/0000-0002-0851-7480
Christin StarzonekInstitute of Anatomy and Experimental Morphology, Center for Experimental Medicine, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Ann-Christin NiehoffInstitute of Inorganic and Analytical Chemistry, University of Münster, Corrensstrasse 28/30, 48149, Münster, Germany.
Uwe KarstInstitute of Inorganic and Analytical Chemistry, University of Münster, Corrensstrasse 28/30, 48149, Münster, Germany.
Jürgen ThomaleInstitute of Cell Biology, Essen University Hospital, Hufelandstrasse 55, 45122, Essen, Germany.
Hartmut SchlüterInstitute of Clinical Chemistry and Laboratory Medicine, Center for Diagnostics, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Carsten BokemeyerDepartment of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Achim AignerRudolf-Boehm-Institute for Pharmacology and Toxicology, Clinical Pharmacology, Härtelstrasse 16-18, 04107, Leipzig, Germany.
Udo SchumacherInstitute of Anatomy and Experimental Morphology, Center for Experimental Medicine, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Universität Hamburg · DEUniversity of Münster · DEEssen University Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A major limitation in the pharmacological treatment of clinically detectable primary cancers and their metastases is their limited accessibility to anti-cancer drugs (cytostatics, inhibitory antibodies, small-molecule inhibitors) critically impairing therapeutic efficacies. Investigations on the tissue distribution of such drugs are rare and have only been based on fresh frozen material or methanol-fixed cell culture cells so far. In this paper, we expand the detection of cisplatin-induced DNA adducts and anthracyclines as well as therapeutic antibodies to routinely prepared formalin-fixed, paraffin-embedded sections (FFPE). Using pre-treated cell lines prepared as FFPE samples comparable to tissues from routine analysis, we demonstrate that our method allows for the detection of chemotherapeutics (anthracyclines by autofluorescence, cisplatin by immune detection of DNA adducts) as well as therapeutic antibodies. This methodology thus allows for analyzing archival FFPE tissues, as demonstrated here for the detection of cisplatin, doxorubicin and trastuzumab in FFPE sections of tumor xenografts from drug-treated mice. Analyzing human tumor samples, this will lead to new insights into the tissue penetration of drugs.

Indexed as

Paraffin EmbeddingAntineoplastic AgentsCetuximabCisplatinDoxorubicinFormaldehydeHumansNeoplasmsRituximabTissue FixationTrastuzumabTumor Cells, CulturedAntineoplastic AgentsCetuximabCisplatinDoxorubicinFormaldehydeRituximabTrastuzumabAgarAntineoplastic agentsCell pelletDNA adductFormaldehydeParaffin embeddingTissue processing

Identifiers

PMID32125512
PMCPMC7225197
OpenAlexW3009754326

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.